Lentiviral expressed growth factors as a novel therapy in wound healing

DESCRIPTION (provided by applicant): Approximately 1 million people are diagnosed with venous leg ulcers annually in the U.S. and another 3 million worldwide. Currently, there are several approaches to wound healing treatment. Recombinant PDGF (Regranex, O rtho-McNeil) has been approved by the Food and Drug Administration (FDA) as a topically applied gel that acts biologically similarly to endogenous PDGF-BB by promoting chemotactic recruitment and proliferation of cells involved in wound repair. The consens us in the wound healing care community is that Regranex exhibited limited potential in clinical use. Despite its limited therapeutic success, Regranex is very expensive and is therefore beyond the means of elderly Medicare patients who represent the majori ty of the chronic wound population. Therefore, new therapies for wound healing are urgently needed. This proposal represents the revised project focused upon developing a novel gene therapy strategy for accelerated wound healing using Self Inactiva ting (SIN) lentiviral vectors (LV) that express hypoxia-inducible factor 1 (HIF-11), a transcription factor known to induce growth factors with wound healing properties. Treatment with HIF-11 expressed in LV might potentially serve as a much better therapy for wound healing than growth factors when applied directly to the wound. LVs are know to stably express genes with high efficiency, so it is hypothesized that stable expression of HIF-11 and HIF-11-induced growth factors at the wound site would lead to a ccelerated wound healing. In Aim 1 of this proposal we will develop SIN lentiviral vector that express HIF-11 as therapeutic payload, as well as control vector expressing green fluorescence protein (GFP). These vectors will also express the mutant human tmpk (TMPK) gene as an excellent safety feature. This suicide gene allows the transduced cells to be eliminated from the body once the wound healing process has been completed, thus limiting any potential complications because of prolonged expression of HIF-1 and growth factors induced by HIF-1 expression. Lentiviral vectors will be manufactured according to standard procedures and quality control will be performed prior to release for testing. In Aim 2 we will test the transduction efficiency of SIN. LV.HIF-11 and SIN.LV.GFP in vitro using mouse embryonic fibroblasts (MEFs). In Aim 3 we will test the ability of the LVs to prolong the expression of HIF-11-induced growth factors and to induce wound healing process at the wound site using diabetic mouse m odel. During Phase I Lentigen Corp. proposes studies that will ultimately generate proof of principle results, leading towards development of a novel, improved and safe gene therapy for the treatment of chronic wounds. Our new therapy is expected to be use d in worldwide clinical settings for treatment of wound healing. PUBLIC HEALTH RELEVANCE This proposal focuses upon developing a novel gene therapy strategy for accelerated wound healing. There are 3.5 million patients with chronic skin ulcers in the U.S. alone (Wound Healing Society, 2003). The global figure is more than 14 million individuals. Two million people with diabetes will develop foot ulcers during their lifetimes. Currently, the only drug available for the treatment of diabetic foot ulcers is Re granex and it has a very limited success. Our new therapy will be affordable and is expected to be used in worldwide clinical settings for treatment of wound healing.